Search results
Better way to treat deadly black widow bites developed | Fox 11 Tri Cities Fox 41 Yakima
FOX 11/41 Yakima· 6 days agoA better way of treating potentially deadly black widow spider bites with fewer side effects has...
Black widow: Human antidotes defeat 1 of world’s most venomous spiders
Interesting Engineering· 6 days agoHust explained selecting the antibodies to Interesting Engineering (IE). Using an innovative...
Novavax seeks FDA approval for updated Covid-19 vaccine
Pharmaceutical Technology via Yahoo Finance· 20 hours agoNovavax has submitted an application to the US Food and Drug Administration (FDA) seeking approval...
No Detriment to RA Starting MTX a Month After PCV13
Medscape· 1 day agoPneumococcal vaccination administered 1 month prior to starting methotrexate (MTX) in patients with rheumatoid arthritis (RA) allows a significantly...
New Antivenom Takes The Sting Out Of Black Widow Spider Bites
IFLScience· 5 days agoA new antivenom for European black widow bites has been developed using engineered human antibodies....
Shoring up blood vessels may offer new approach for treating autoimmune rheumatic diseases
Medical Xpress· 16 hours agoA study from physician-scientists at the Hospital for Special Surgery (HSS) points to a potential...
Study finds new treatment for ulcerative colitis
Medical Xpress· 11 hours agoThe medication, guselkumab (Tremfya), is an antibody that blocks IL-23, the cytokine that drives many immune diseases, including ulcerative colitis. The...
FDA halts trial of BioNTech-MediLink ADC over 'significant risk of illness'
FierceBiotech· 16 hours agoThe FDA has slammed the brakes on a trial of MediLink Therapeutics’ BioNTech-partnered antibody-drug...
'General Hospital's John J. York Talks Returning After Cancer Battle
Entertainment Tonight· 14 hours agoGeneral Hospital star John J. York became emotional while discussing his battle with cancer and the...
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory...
The Port Lavaca Wave· 5 days ago- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD)